Cero Therapeutics Holdings, INC 8-K filings

Cero Therapeutics Holdings, Inc. has entered into a second amended and restated promissory note, securing up to $2,085,200 in aggregate principal amount with SRX Global Inc.

CERo Therapeutics Holdings, Inc. has entered into an amended and restated convertible promissory note agreement for up to $1.41 million in total funding.

CERo Therapeutics Holdings, Inc. has entered into a $750,000 convertible promissory note agreement with SRX Health Solutions, Inc. to bolster its capital position.

CERo Therapeutics Holdings, Inc. has entered into a convertible promissory note agreement for up to $1 million in financing.

Cero Therapeutics Holdings, Inc. has issued a $350,000 convertible promissory note to Keystone Capital Partners, LLC, with a potential to draw up to $1,000,000.

CERO Therapeutics Holdings, Inc. announced a new $750,000 convertible note financing, a change in its independent auditor, and the appointment of Eric Francois to its board of directors.

CERO Therapeutics presents first-in-human clinical data for CER-1236, a TIM-4 based CAR-T therapy, showing a favorable safety profile without cytokine release syndrome.

CERO Therapeutics Holdings, Inc. announced that the Nasdaq Listing and Hearing Review Council affirmed the decision to delist the company's securities from Nasdaq.

CERo Therapeutics announced encouraging safety data and a significant platelet transfusion-free interval in its Phase 1 CertainT-1 trial for AML, leading to an expansion of the study to include MDS and MF patients.

CERO Therapeutics Holdings' stockholders approved a reverse stock split, a significant increase in its equity incentive plan, and a preferred stock conversion at a special meeting.

CERO Therapeutics Holdings, Inc. has entered into a new purchase agreement with Keystone Capital Partners, LLC for up to $14.6 million in common stock, continuing its equity line program.

CERO Therapeutics announced its common stock will be suspended from trading on Nasdaq on October 31, 2025, after failing to meet the minimum stockholders' equity requirement.

CERO Therapeutics Holdings, Inc. completed an initial closing of $2.25 million from its Series E convertible preferred stock offering, part of a larger $7 million financing round.

CERo Therapeutics Holdings, Inc. has entered into a Securities Purchase Agreement to raise up to $7 million through the issuance of Series E convertible preferred stock to accredited investors.

CERO Therapeutics Holdings, Inc. updated its corporate presentation, highlighting a novel cell therapy platform and upcoming clinical milestones for its lead candidate, CER-1236.

CERo Therapeutics Holdings, Inc. announced that its lead investigational compound, CER-1236, received FDA Fast Track Designation for Acute Myeloid Leukemia, enhancing its regulatory and financial advantages.

CERO Therapeutics Holdings, Inc. received a Nasdaq delisting notice due to non-compliance with the minimum stockholders' equity requirement, but has appealed the decision.

CERO Therapeutics Holdings, Inc. announced the completion of an additional closing in its private placement offering, raising approximately $397,600 through the sale of 497 shares of Series D convertible preferred stock.

CERo Therapeutics Holdings, Inc. has entered into a new common stock purchase agreement with Keystone Capital Partners, LLC, allowing the company to raise up to an additional $17.49 million, completing its aggregate $25 million equity line program.

CERO Therapeutics Holdings, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, ensuring its common stock will continue to be listed on The Nasdaq Capital Market.

CERO Therapeutics Holdings, Inc. announced an amendment to its securities purchase agreement, bringing in new institutional investors and completing an additional closing of Series D Preferred Stock, raising approximately $1.85 million.

CERo Therapeutics Holdings, Inc. announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to its lead drug candidate, CER-1236, for the treatment of acute myeloid leukemia.

CERO Therapeutics Holdings, Inc. received a Nasdaq delisting notice for failing to meet the minimum bid price requirement and subsequently executed a 1-for-20 reverse stock split to regain compliance.

CERo Therapeutics Holdings, Inc. has enacted a 1-for-20 reverse stock split, effective June 13, 2025, to increase its per-share price and comply with Nasdaq listing standards.

CERO Therapeutics Holdings, Inc. announced an additional closing of its Series D private placement, securing approximately $750,400 from institutional investors to further advance its innovative T cell immunotherapy programs.

CERo Therapeutics Holdings, Inc. has transitioned its Chief Executive Officer, Chris Ehrlich, and Chief Financial Officer, Andrew Albert Kucharchuk, from consulting roles to full-time employment with new agreements detailing their compensation, performance bonuses, and equity awards.

CERO Therapeutics Holdings, Inc. announced that its stockholders approved a 1-for-20 reverse stock split, an increase of 2,000,000 shares for its equity incentive plan, and the election of two Class I directors at its 2025 Annual Meeting.

CERo Therapeutics Holdings, Inc. has regained compliance with Nasdaq's minimum stockholders' equity requirement of $2.5 million, ensuring continued listing on the Nasdaq Capital Market.

CERO Therapeutics Holdings, Inc. announces the filing of a Certificate of Designations for Series D Preferred Stock and updates its corporate presentation for investors.

CERo Therapeutics Holdings, Inc. announces a securities purchase agreement for a Series D convertible preferred stock transaction, expecting up to $8 million in gross proceeds to advance its engineered T cell therapeutics.